Understanding better the Impact of Long COVID on Health
(Credit: pexels)

News

Understanding better the Impact of Long COVID on Health

28 Feb, 2022

Published over 4 years ago. See the latest and most current information on News.

International researchers from the University of Oxford, the University of Wisconsin School of Medicine and Public Health, Royal Brompton Hospital and Imperial College, London and the University of Zurich, Switzerland have conducted a review on the wide-ranging effects of Long COVID and the associated issues for healthcare providers, specifically highlighting impact on the cardiovascular system.

Spanning each step from a patient’s original coronavirus infection and direct impacts, such as myocardial infarction or inflammatory myocarditis, to the long-term impacts on aspects of wellbeing such as mental health and fatigue, the team concluded that current evidence for the treatment of long COVID is lacking and that our current understanding of pathophysiological mechanisms and treatment options remains limited.

The review also found that the vast inequalities in healthcare provision exposed by COVID-19 continue to be magnified by long COVID and called for global humanitarian efforts to promote and fund equitable access to healthcare, social and welfare support and vaccines across the world.

Dr Betty Raman, of Oxford’s Radcliffe Department of Medicine, said: 'Long COVID is emerging as a major public health issue, which makes it important that we better understand the long-term effects of COVID-19 to improve our treatment of it. This review highlights the wide range of short and long-term health impacts and the mechanisms behind them, which is key to providing treatment and ongoing care.'

Professor Stefan Neubauer, Head of the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, said: 'Long COVID is a huge medical challenge. This review gives a comprehensive update on its effect on the cardiovascular system and will also be important in guiding future research into the condition and for finding new treatments.'

Dr Raman is leading one of the first randomised, double-blind, placebo-controlled studies in the UK. Other trials to date have been open label or non-random assignment of therapy. The team’s work is supported by the NIHR Oxford Biomedical Research Centre, a partnership between Oxford University Hospitals NHS Foundation Trust and the University of Oxford.

The full paper, ‘Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus’, can be read in the European Heart Journal.

More information online

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Environmental sample extraction: moving beyond the limitations of EPA Method 3546
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
What happens when a refinery suddenly stops?
Explore more Arrow
Chromatography Today
UHPLC–MS/MS methodology detects multiple algal toxins in fish plasma
Explore more Arrow